Philip A. Serbin, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 701 Mcfarland St, Morristown, TN 37814 Phone: 423-581-6084 Fax: 423-581-6078 |
Jose G Amador Jr, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 421 No High St, Morristown, TN 37814 Phone: 423-581-1520 Fax: 423-581-7968 |
Kelly E Bewsey, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 701 Mcfarland St, Morristown, TN 37814 Phone: 423-581-6084 Fax: 865-374-2140 |
Jack A Monnig, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 2845 W Andrew Johnson Hwy, Morristown, TN 37814 Phone: 423-587-8009 Fax: 423-289-1607 |
News Archive
Mylan Pharmaceuticals ULC, the Canadian subsidiary of Mylan Inc., today received approval from Health Canada for Mylan-Rosuvastatin Calcium Tablets, 5mg, 10mg, 20mg and 40mg. Mylan-Rosuvastatin is the generic version of Astra Zeneca's Crestor Tablets, which are used for the management of primary hypercholesterolaemia, mixed dyslipidaemia, and familial hypercholesterolaemia.
Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.
Colonoscopy in children is a highly specialized procedure which is not often performed in the Chinese population. Data of its safety and diagnostic yield in Chinese children is scarce. One of the most common indications for colonoscopy in children of western countries is investigation and follow-up assessment for inflammatory bowel disease which is uncommon in Chinese children. It has recently been reported that there is increasing occurrence of childhood inflammatory bowel disease in western countries. It is, however, unknown whether a similar increase happens in Chinese children.
Researchers from the Harvard School of Public Health and the Karolinska Institute in Stockholm, Sweden, have found no association between acrylamide intake in foods and risk of breast cancer among Swedish women. The findings appear in the March 16, 2005 issue of the Journal of the American Medical Association.
Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.
› Verified 8 days ago